Dennehy Colum, Conroy Michael R, Forde Patrick M
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Cancer. 2025 May 15;131(10):e35849. doi: 10.1002/cncr.35849.
Lung cancer remains a significant global health challenge, demanding innovative treatment strategies. Immune checkpoint blockade has revolutionized cancer care, leading to improved survival across advanced malignancies and has now become a standard therapy for earlier stage, resectable lung cancer. This review article consolidates the current landscape and future prospects of neoadjuvant and perioperative immunotherapy in lung cancer. The authors outline key findings from clinical trials in resectable lung cancer, including early efficacy, safety profiles, and emerging impact on disease recurrence, and overall survival. Additionally, this review elucidates the challenges encountered, including patient selection criteria, optimal treatment schedules, immune-related adverse events, and impact on surgery. This comprehensive analysis amalgamates current evidence with future directions, providing a roadmap for clinicians, researchers, and stakeholders to navigate the dynamic realm of immunotherapy for surgically resectable lung cancer.
肺癌仍然是一项重大的全球健康挑战，需要创新的治疗策略。免疫检查点阻断疗法彻底改变了癌症治疗模式，提高了晚期恶性肿瘤患者的生存率，如今已成为早期可切除肺癌的标准治疗方法。这篇综述文章总结了肺癌新辅助和围手术期免疫治疗的现状及未来前景。作者概述了可切除肺癌临床试验的关键发现，包括早期疗效、安全性概况以及对疾病复发和总生存期的新影响。此外，本综述还阐明了所遇到的挑战，包括患者选择标准、最佳治疗方案、免疫相关不良事件以及对手术的影响。这项全面分析将当前证据与未来方向相结合，为临床医生、研究人员和利益相关者提供了一份路线图，以引领他们在可手术切除肺癌免疫治疗这一动态领域中前行。
